Mykronor (Noradrenaline Tartrate)

Noradrenaline tartrate, the active ingredient in Mykronor, is a sympathomimetic agent presented as an injectable solution for intravenous use. It is employed to raise blood pressure and improve cardiac output in patients with acute hypotension, septic shock, cardiogenic shock, or cardiac arrest when used as a vasopressor.

GNH USA supplies Mykronor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Mykronor is a vasopressor that acts on the sympathetic cardiovascular pathway to restore adequate perfusion in critical care settings.

Acute hypotension: raises systemic blood pressure to maintain organ perfusion. Septic shock: counteracts vasodilatory shock by constricting peripheral vessels. Cardiogenic shock: supports cardiac output while improving coronary perfusion. Cardiac arrest: provides rapid vasoconstriction during resuscitation efforts.

Mykronor may cause a range of adverse reactions that clinicians monitor during infusion.

Common Side Effects: - Headache: transient and often related to rapid blood pressure changes. - Palpitations: due to beta‑1 stimulation of the heart. - Peripheral ischemia: reduced blood flow to extremities. - Nausea or vomiting: occasional gastrointestinal response.

Serious or Rare Side Effects: - Cardiac arrhythmias: potentially life‑threatening rhythm disturbances. - Severe hypertension: excessive rise in blood pressure. - Tissue necrosis at infusion site: if extravasation occurs. - Myocardial ischemia: reduced oxygen supply to heart muscle.

Mykronor requires careful monitoring and specific safety measures before and during administration. - Dose titration: adjust infusion rate based on continuous blood pressure and cardiac monitoring. - Cardiac history: avoid rapid escalation in patients with known ischemic heart disease. - Extravasation risk: use a dedicated IV line and inspect the site frequently. - Drug compatibility: do not mix with solutions that may precipitate or inactivate the catecholamine. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mykronor can interact with several agents that affect cardiovascular tone or catecholamine metabolism.

Major Interactions (Avoid): - Beta‑blockers: may blunt the intended increase in heart rate and contractility. - MAO inhibitors: can potentiate hypertensive responses.

Moderate Interactions (Monitor Closely): - Tricyclic antidepressants: may enhance vasoconstrictive effects. - Calcium channel blockers: can alter vascular response and require dose adjustments. - Diuretics: may affect intravascular volume and influence blood pressure targets.